PD-L1 Specific 68Ga-THP-PD-L1-3 Probe for PET Imaging in Solid Tumors

Launched by HUA ZHU · Apr 22, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging technique called 68Ga-Nb-1 PET/CT, which aims to detect a specific protein, PD-L1, on tumors in patients with solid tumors. By identifying whether PD-L1 is present, doctors hope to better understand which patients may benefit from a type of cancer treatment known as anti-PD-L1 therapy. The study is currently looking for participants aged 18 and older who have solid tumors and can provide measurable tumor samples.

To be eligible, participants should be in relatively good health, with a life expectancy of at least 12 weeks, and should not have serious liver or kidney problems. Those who are pregnant, have certain mental health conditions like claustrophobia, or cannot stay still for a half-hour won't be able to participate. If you join the trial, you can expect a noninvasive imaging procedure that will help researchers learn more about your cancer and its potential treatment options. Your involvement could contribute to important advancements in cancer care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Aged \>18 years old; ECOG 0 or 1;
• • 2. Patients with solid tumorsin or suspected tumor lesions;
• • 3. life expectancy \>=12 weeks.
• Exclusion Criteria:
• • 1. Significant hepatic or renal dysfunction;
• • 2. Is pregnant or ready to pregnant;
• • 3. Cannot keep their states for half an hour;
• • 4. Refusal to join the clinical study;
• • 5. Suffering from claustrophobia or other mental diseases;
• • 6. Any other situation that researchers think it is not suitable to participate in the experiment